Stalicla
- Company typePrivate
- Founded2017
- HeadquartersGenève, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
Stalicla firmographics
Firmographics- Name
- Stalicla
- Legal name
- STALICLA SA
- Website
- https://stalicla.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Stalicla industry classification
Industry- Product category
- Clinical-stage precision biopharmaceuticals for neurodevelopmental disorders
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
Keywords
Where Stalicla is headquartered
LocationHeadquarters
- HQ city
- Genève
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Stalicla business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Licensing and Milestone Payments: Biopharmaceutical company developing precision medicines for neurodevelopmental disorders. Revenue will be generated through licensing deals, development and commercial milestones, and royalties from drug sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Stalicla product offering
Product offeringCore offering
Stalicla develops precision medicines for neurodevelopmental and neuropsychiatric disorders through its proprietary DEPI platform, which applies AI and multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The pipeline includes three clinical-stage drug candidates: STP1 (ibudilast/bumetanide combination for ASD-Phen1 subgroup), STP2/SFX-01 (stabilized sulforaphane for ASD-Phen2, in-licensed from TheraCryf), and STP7/Mavoglurant (mGluR5 NAM licensed from Novartis for cocaine use disorder and ASD-Phen7).
Product overview
STALICLA's core offering is the DEPI (Databased Endophenotyping Patient Identification) precision neuro medicine platform, which uses AI-driven multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The company's pipeline includes three therapeutic candidates: STP1 (fixed dose combination of ibudilast and bumetanide for ASD-Phenotype 1), STP2 (stabilized sulforaphane for ASD-Phenotype 2), and STP7 (mavoglurant, an mGluR5 NAM for cocaine use disorder and ASD). The company also offers DEPI as a platform for industry partners to de-risk drug development in neurodevelopmental and neuropsychiatric disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- DEPI (Databased Endophenotyping Patient Identification) Platform AI-driven precision neuro medicine platform that uses multiomics analysis (genomics, transcriptomics, proteomics, pharmacogenomics), patient data, and machine learning to identify patient subgroups with similar disease signatures and match them with tailored drug treatments for neurodevelopmental and neuropsychiatric disorders.
- STP1 Fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) tailored as a precision medicine treatment candidate for ASD-Phenotype 1 subgroup patients, targeting improvements in executive function and memory. Completed Phase 1b trials with demonstrated safety and dose-dependent target engagement.
- STP2 (SFX-01) Stabilized synthetic form of sulforaphane (patented composition of sulforaphane and alpha cyclodextrin) developed as a precision medicine treatment candidate for ASD-Phenotype 2 subgroup, in-licensed from TheraCryf (formerly Evgen Pharma).
- STP7 (Mavoglurant) Most clinically advanced negative allosteric modulator of glutamate receptor 5 (mGluR5 NAM), licensed from Novartis and being developed for cocaine use disorder (Phase 3 with NIH/NIDA funding) and ASD Phen7 subgroup. Over 1,800 patients administered in Phase 2 trials up to 2 years.
- NGSTroubleFinder Open-source tool for detection and quantification of contamination and kinship across human NGS data, with sample identity verification and cross-sample contamination detection. Written in Python with a custom parallelized pileup engine in C.
Quantifiable outcome
- Phase 1b trials showed STP1 was well-tolerated with dose-dependent target engagement and improvements in executive function and memory
- +3 more outcomes
Companies that use Stalicla
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Stalicla technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Stalicla partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, strategic and minor.
- Dr. Paulo FontouracoreAppointed as Chief Scientific and Clinical Development Advisor. Former Global Head of Neuroscience Clinical Development at Roche with 16 years tenure. Brings expertise in CNS drug development and neurodevelopmental disorders.
- Firefly NeurosciencestrategicPartnership to validate EEG-based biomarkers using Firefly's FDA-cleared BNA platform in Stalicla's biologically-enriched ASD subgroups. Leverages DEPI platform and BNA technology for Phase 2 trials.
- National Institute on Drug Abuse (NIDA)coreCRADA agreement covering Phase 3 clinical trial for mavoglurant in cocaine use disorder, enrolling up to 330 patients. NIDA covers trial costs under its own account. NIH-NIDA fully funds Phase 3 development.
- NovartiscoreExclusive in-licensing agreement for mavoglurant (STP7) worldwide for substance-use disorders, NDDs, and other indications. Up to $270M in milestones plus royalties. Novartis also took equity stake in Stalicla.
- Evgen Pharma / TheraCryfcoreIn-licensing agreement for SFX-01 (STP2) worldwide for neurodevelopmental disorder indications. STP2 is a patented composition of sulforaphane and alpha cyclodextrin for ASD-Phen2 subgroup.
- REPO4EU ConsortiumstrategicEU-funded project (€22M total funding) for Euro-Global Platform for Mechanism-based Drug Repurposing. Stalicla leads computational drug repositioning work package with €1.7M allocated budget over 6 years.
- Universitat Autònoma de Barcelona / IBB UABminorCollaborative research partnership in biotechnology, genetics and biomedical engineering.
- Cincinnati Children's HospitalcorePhase 1b clinical trial site for STP1 with Dr. Craig Erickson as principal investigator. Successfully completed Phase 1b trials demonstrating safety and target engagement.
- Greenwood Genetic Center (GGC)strategicLong-term research partnership for ASD clinical trials. GGC provides autism patient cohorts (several hundred patients with documented records). Dr. Walter Kaufmann joins scientific committee; Dr. Luigi Boccuto served as Chief Scientific Officer.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
Stalicla competitors and assessment
Company assessmentDirect peers
- Neumora Therapeutics: Clinical-stage precision medicine company focused on CNS and neuropsychiatric disorders using data-driven patient stratification. Directly comparable to Stalicla's DEPI platform approach of matching therapies to defined patient subtypes.
- Sage Therapeutics: CNS-focused biopharma developing CNS therapeutics for depression, epilepsy, and rare neurodevelopmental disorders. Comparable clinical-stage CNS pipeline strategy and similar small-molecule repurposing model in brain disorders.
- Acadia Pharmaceuticals: Commercial-stage CNS specialty pharma focused on neurological and psychiatric disorders, including autism-related indications (e.g., Rett syndrome via trofinetide partnership). Comparable CNS franchise focus and small-molecule development approach.
- MapLight Therapeutics: Clinical-stage precision neuroscience company targeting CNS disorders including schizophrenia and autism using circuit-based approaches. Comparable emphasis on defined patient populations and CNS pipeline focus.
- Axial Therapeutics: Clinical-stage biotech developing gut-brain targeted therapies for autism and Parkinson's disease. Directly comparable focus on biologically-defined ASD subgroups and CNS precision medicine.
- Karuna Therapeutics: CNS precision medicine biotech that developed xanomeline-trospium for schizophrenia and was acquired by BMS. Comparable CNS precision-medicine approach and clinical-stage development model in neuropsychiatric indications.
- BioXcel Therapeutics: Clinical-stage biopharma using AI-driven drug discovery and repurposing for CNS and immuno-oncology indications. Comparable AI-driven approach to CNS drug development and repurposing of existing compounds.
Emerging players
- Yamo Pharmaceuticals: Earlier-stage biotech developing CNS therapeutics for autism and other neurodevelopmental disorders. Comparable therapeutic focus area in ASD, though at earlier development stage with different mechanistic approach.
Broad incumbents
- Roche: Global pharma with a large neuroscience franchise including therapies for Fragile X, SMA, Huntington's, and autism-related conditions. Relevant because Dr. Paulo Fontoura (Stalicla's CSO advisor) led Roche's neuroscience clinical development for 16 years, signaling overlapping CNS development priorities.
- Novartis: Global pharma that originally developed mavoglurant and out-licensed it to Stalicla for $270M in milestones. Comparable as a major CNS player and the originator of Stalicla's most advanced clinical asset.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Stalicla social profiles
Digital presenceStalicla financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stalicla leadership team
Management profileNumber of profiles
Profiles18 records
Stalicla subsidiaries and ownership
Company hierarchySubsidiaries1 record
Stalicla funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stalicla M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stalicla
What does Stalicla do?
Stalicla develops precision medicines for neurodevelopmental and neuropsychiatric disorders through its proprietary DEPI platform, which applies AI and multiomics analysis to identify biologically-defined patient subgroups and match them with tailored drug treatments. The pipeline includes three clinical-stage drug candidates: STP1 (ibudilast/bumetanide combination for ASD-Phen1 subgroup), STP2/SFX-01 (stabilized sulforaphane for ASD-Phen2, in-licensed from TheraCryf), and STP7/Mavoglurant (mGluR5 NAM licensed from Novartis for cocaine use disorder and ASD-Phen7).
Is Stalicla a public or private company?
Stalicla is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stalicla founded?
Stalicla was founded in 2017. It employs 11 to 50 people.
Where is Stalicla based?
Stalicla is headquartered in Genève, Switzerland, in the Europe region.
How does Stalicla make money?
One revenue line is on record: licensing and Milestone Payments.
Who are Stalicla's main competitors?
Direct peers on record are Neumora Therapeutics, Sage Therapeutics, Acadia Pharmaceuticals, MapLight Therapeutics, Axial Therapeutics, Karuna Therapeutics and BioXcel Therapeutics. Yamo Pharmaceuticals is listed as an emerging player. Broad incumbents are Roche and Novartis.
Does Stalicla have an API?
No public API is recorded for Stalicla.
What industry is Stalicla in?
Stalicla's product category is Clinical-stage precision biopharmaceuticals for neurodevelopmental disorders. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.